OmniScience and INmune Bio Partner for Alzheimer’s Trial

Exec Edge
05 Dec 2024

By Karen Roman

OmniScience and INmune Bio, Inc. (Nasdaq: INMB) said they’re using genAI in an Alzheimer’s disease trial.

The AI will support the live clinical trial and is expected to increase efficiency and the probability of success, both companies said in a statement.

“OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” said Angela Holmes, OmniScience’s CEO.

Contact:

Exec Edge

Editor@executives-edge.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10